"Pending decisions by the Supreme Court, the patent office, and Congress could fundamentally change the ground rules for patent protection within the life sciences industry to such a degree that in a decade we may not have an industry remaining," Alnylam Pharmaceuticals CEO John M. Maraganore writes in a Boston Globe opinion piece. However, there is "still time" for the Senate to alter the pending legislation "in light of its potentially devastating impact upon biomedical research," he writes.

Related Summaries